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BACKROUND  
Hodgkin lymphoma (HL) is a lymphoid malignancy of B-cell origin with an high probability of long-term survival.Despite 
high efficacy of frontline therapy, about 30% of patient will show relapse or refractory disease (R/R). In this patient 
population, the treatment of choice consists of salvage chemotherapy  followed by intensive conditioning regimen 
and autologous stem cell transplantation (ASCT). However 30-50% of patient receiving salvage chemotherapy fail to 
achieve at least PR and further therapy with Brentuximab-Vedotin (BV) may be administered to induce a clinical 
response. BV may be further used as post-ASCT consolidation therapy, especially in patient who receive ASCT in PR. 
However therapeutic options for truly refractory patients are still limited. 
Recently, the efficacy of immune-check point inhibitors have been explored in HL and the PD-1 targeting antibody 
Nivolumab, has shown promising results in HL patients relapsed after ASCT. Nivolumab is currently approved with this 
indication. Unfortunately, expected CR rate is only about 20%. Thus, we reasoned that earlier administration of 
nivolumab, as post-ASCT consolidation, may improve its efficacy. However, several reports have highlighted the 
importance of patient immune-competence, which is severely impaired in heavily pre-treated lymphoma patients 
undergoing ASCT, to achieve durable response with anti-PD1 immunotherapy. In this view, there is a strong rationale 
for reinfusing autologous lymphocytes, early after ASCT, concomitant with anti-PD1 consolidation immunotherapy in 
very high risk HD patients. 
AIMS OF THE STUDY 
Here we report the preliminary results of a prospective trial investigating the feasibility, and the efficacy, in terms of 
both immunological recovery and clinical response, of post-ASCT Nivolumab with the support of unselected 
autologous lymphocyte reinfusions (ALI). 
 
METHODS 
Patients under the age of 60 with high risk HD identified by PET2 or PET6 positivity following ABVD, were scheduled 
for a pre-emptive lymphocyte apheresis, with a target of 5x107 CD3+/kg. Patients who failed to achieve at least  PR 
with salvage chemotherapy proceeded to ASCT with FEAM conditioning followed by early Nivolumab and ALI. The first 
ALI was performed 7 days after engraftment;  the second ALI was administered at day +14 after the first dose whereas  
the third and the fourth doses were given every 21 days. ALI dosing was incremental, one logarithm at each infusion, 
starting from 1x104T cells/kg in the first infusion to a maximum of 1x107/kg in the fourth and last infusion. Each ALI 
was followed within 48 hours by the administration of Nivolumab 240 mg flat dose. 
Toxicity was evaluated and graduated according to CTCAE-EORTC standards. Circulating Lymphocyte subpopulations 
were extensively studied before and after each ALI and each Nivolumab administration by 12-colours flow cytometry. 
Clinical response was evaluated 21 days after completion of the fourth ALI + Nivolumab. 
PRELIMINARY RESULTS 
FourR/R HD patient have completed the treatment  and 3are currently under treatment. All patient failed to achieve 
CR with first and second line chemotherapy and then progressed during BV therapy. PET scan before ASCT showed 
progressing disease in all patient, with multiple-extra nodal involvement in 3 of them.  All patient  underwent ASCT 
with FEAM conditioning and achieved complete engraftment after a median of 10 days (8-12).  
Compared to HD patients receiving the same conditioning without ALI, in all patients a quicker immune-recovery in 
term of CD3+ count was achieved at all timepoints (p <0.05). After ALI administration, cytotoxic (CD56+,CD16+,CD57+) 
NKcells  showed the most significant consistent increase (Fig. 1, p<0.05). Nivolumab administration by itself 
determined only a modest and transient increase in T-effector population. No grade 3 or 4 adverse events were 
recorded so far. In one patient grade 2 fever was observed after 1st ALI. All treated patient achieved negative  PET scan 
after the procedure and are alive and disease-free after a median follow-up of 9 months.  
PRELIMINARY CONCLUSIONS 
Post-ASCT ALI proved to be feasible and effectiveallowing a faster immune recovery in heavily-pre-treated HD 
patients.Moreover, the early administration of check point inhibitors combined with ALI as post-ASCT consolidation 
therapy,  may improve the low rate of CR expected with anti-PD1 blockade alone, providing a more effective option 
for refractory patient, which are usually considered not candidate for ASCT. 
  
 




1. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management..Am J Hematol. 2016 Jun;91(4):434-42.  
2. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with 
refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free 
survival in patients treated at first recurrence. Cancer 2003;97(11):2748-2759. 
3. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 
2015;372(4):311-319. 
4. Zaragoza J, et al. Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall 
survival in patients with melanoma. Br J Dermatol. 2015 
5. Boulassel MR, Herr AL, deB Edwardes MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is 
associated with better survival in younger patients with lymphoproliferative disorders. Hematology. 2006 Jun;11(3):165 -70. 
6. T-Cell Research Novel multicolor flow cytometry tools  for the study of CD4+ T-cell differentiation and plasticity.BD 23-11591-02. 
https://www.bdbiosciences.com/documents/tcell_brochure.pdf 
7. The EBMT Handbook of Haematopoietic Stem Cell Transplantation. Copyright 2012-2013 ESH & EBMT. Avaible online at 
https://ebmtonline.forumservice.net/. 
 
 
